

Closed-Loop Therapies as Adaptive Medicines




Timothy Lu, M.D., Ph.D. Associate Professor MIT EECS and BioEng February 22, 2016


Plii

Synthetic Biology – From Cut & Paste to Programming DNA




Programming Adaptive Medicines with Synthetic Biology








Fischbach, Bluestone, Lim































Too much therapy




Sense and reduce therapy




Sense and maintain homeostasis

Need for New Technologies to Modulate the Human Microbiome

- Human body is shared with trillions of commensal microbes
- Involved in:
 - Development
 - Immunity
 - Digestion
 - Mood/Behavior
- Tools to manipulate microbiota crude and poorly understood
 - Antibiotics
 - Probiotics
 - Prebiotics






Additive


Subtractive

11111

Applications of Synthetic Biology to Microbiome Engineering




Digital and Analog Paradigms for Computing and Memory




Daniel et al. Nature 2013

Farzadfard et al. Science 2014


Incorporating History into Sense-and-Respond Circuits






M. Fussenegger – ETH Zurich

Шii




M. Fussenegger – ETH Zurich


Obesity Treating Cell Circuits




Obesity Treating Cell Circuits




Cell Therapy for Graves' Disease





Cell Therapy for Psoriasis



Technical Challenges

- Designing state-dependent cell therapies
- Creating circuits that match the time-scale of desired responses
- Building robustness into closed-loop therapies
 - Redundancy? Multiple-feedback loops? Isolation strategies to minimize environmental effects?
- Designing cellular sensors for a wide range of analytes
- Ensuring specificity of cellular sensing circuits for desired disease states
- Maximizing the durability of closed-loop therapeutics despite evolving cellular background
- Choosing best delivery method or chassis introducing desired therapeutic effect into humans
 - Engineered bacteria or human cells? Gene therapies via non-viral or viral vectors?

- What are the best indications for the first clinical applications, balancing risk / benefit?
- How to do preclinical modeling of closed-loop therapies in vitro and animals?
- How to characterize the pharmacodynamics / pharmacokinetics of closed-loop therapies?
- How to quality-control the manufacturing of closed-loop therapies?
- How to monitor the *in vivo* performance of closed-loop therapies when introduced into patients?
- How to measure the long-term durability of closed-loop therapies?
- How to incorporate safeguards or external control over closed-loop therapies?
- How does this fit into existing regulatory frameworks? Do these make sense?
 - When in the process does environmental risk assessment come into play?
 - How are fecal transplants regulated?



timlu@mit.edu

We are hiring for talented and motivated researchers!

Mii